Participants 0 182 5
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
Participants 464 518 6
patients with hormone-receptor-positive breast cancer.
Participants 527 589 4
We did this phase 2 trial in outpatient clinics and hospitals.
Participants 590 744 7
We enrolled postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment.
Participants 1437 1536 6
We screened 189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group).
Participants 2501 2601 4
 treatment in women with previously treated hormone-receptor-positive locally advanced or metastatic
